The Emerging Growth Company Council (EGCC) is the division within AdvaMed dedicated to the needs of smaller medical technology manufacturers.
In recognition of the challenges facing small companies, the Emerging Growth Company Council was reorganized and expanded in December 2011 as the newest division of AdvaMed to bring greater focus to issues facing companies with annual U.S. sales of less than $100 million. It is the vision of the EGCC to be the leader in advancing medical technology by bolstering the industry’s emerging and early-growth enterprises – the drivers of disruptive innovation, job creation, and economic expansion.
Governed by the EGCC Board of Directors, this division is committed to ensuring the voice of small pioneering and entrepreneurial companies is always heard by policymakers. The EGCC focuses on facilitating a policy environment conducive to capital formation and innovation, advocating for domestic and international payment and regulatory policies that are favorable to emerging companies, and providing educational meetings and opportunities for emerging and early-growth company leaders and professionals.
As with AdvaMedDx, EGCC members enjoy full access to AdvaMed’s policy expertise and other resources – in all clinical areas. EGCC members also have the opportunity to participate in small-company focused programming to support their survival and growth.
In this video, President and CEO of CVRx and AdvaMed EGCC Board Chairman, Nadim Yared, discusses the benefits of an AdvaMed membership.
We provide resources to help you commercialize your products more efficiently in today’s evolving business environment , at a very affordable membership cost of as little as $799. If your company's manufactured domestic (U.S.) sales of FDA regulated products are $30 million, or less you are eligible apply for and pay dues membership online .
Emerging Growth Companies receive the same membership benefits as larger member companies plus additional benefits that meet your specific needs. Join your colleagues! Be the Leading Voice for changing laws, regulations, and policies affecting the timely commercialization of your products into U.S. and international markets. Learn more about our efforts in AdvaMed's EGCC Strategic Overview.
EGCC Membership is open to medical technology firms worldwide with annual U.S. revenue of less than $100 million. To be eligible for membership, your company must meet the following criteria:
- Manufacture a medical device, diagnostic product, or medical information system for sale in the United States
- Performing research and development in these areas, but not yet manufacturing or earning revenue from the U.S. market.